• Home
  • Tutorial
  • TCGA
  • CPTAC
  • CBTTC


Select cancer

    Bladder urothelial carcinoma▼
    Neuronal Basal-squamous Luminal Luminal-Infiltrated Luminal-Papillary TP53 Mutant
    Breast invasive carcinoma ▼
    TNBC HER2+ve Luminal TP53 Mutant
    Colon adenocarcinoma ▼
    Adenocarcinoma Mucinous adenocarcinoma TP53 Mutant
    Esophageal carcinoma ▼
    Adenocarcinoma Squamous cell carcinoma
    Prostate adenocarcinoma ▼
    ETS-Fusion No ETS-fusion ERG-fusion TP53 Mutant
    Uterine Corpus Endometrial Carcinoma ▼
    Endometrioid Serous Mixed TP53 Mutant
    Thyroid carcinoma ▼
    Classical type Follicular cell Tall cell
    Stomach adenocarcinoma ▼
    Adenocarcinoma NOS Adenocarcinoma Diffuse Adenocarcinoma Signet Ring Intestinal Adenocarcinoma NOS Intestinal Adenocarcinoma Tubular Intestinal Adenocarcinoma Mucinous TP53 Mutant
    Rectum adenocarcinoma ▼
    Adenocarcinoma Mucinous adenocarcinoma
    Lung adenocarcinoma ▼
    LUAD Not Otherwise Specified LUAD Mixed Subtype Brochioloalveolar Carcinoma Non mucinous Lung Acinar Adenocarcinoma Mucinous (Colloid) Carcinoma Lung Papillary Adenocarcinoma TP53 Mutant
    Lung squamous cell carcinoma ▼
    LUSC Not Otherwise Specified Lung Basaloid Squamous Cell Carcinoma TP53 Mutant
    Kidney renal clear cell carcinoma ▼
    ccA subtype ccB subtype
    Kidney renal papillary cell carcinoma ▼
    Type1 papillary subtype Type2 papillary subtype CIMP Unclassified papillary subtype
    Head and Neck squamous cell carcinoma ▼
    TP53 Mutant
    Liver hepatocellular carcinoma ▼
    TP53 Mutant
    Sarcoma ▼
    TP53 Mutant
    Glioblastoma multiforme ▼
    TP53 Mutant
    Pancreatic carcinoma ▼
    TP53 Mutant
    Skin cutaneous melanoma ▼
    TP53 Mutant
    Lymphoid Neoplasm Diffuse Large B-cell Lymphoma ▼
    TP53 Mutant
    Uterine Carcinosarcoma ▼
    TP53 Mutant
    Brain low grade glioma ▼
    TP53 Mutant
    Mesothelioma ▼
    TP53 Mutant
    Ovarian serous cystadenocarcinoma ▼
    TP53 Mutant
    Adrenocortical carcinoma ▼
    TP53 Mutant
    Kidney chromophobe

 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
Show other samples
 Previous 





 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
Show other samples
 Previous 



© bcrf

Home | Tutorial | Analysis | About Us | Contact Us | Citations | Donate | Twitter
Please cite: Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVSK and Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, N.Y.) 19(8):649-658. August 2017